article thumbnail

Automation to accelerate biopharma in next decade

European Pharmaceutical Review

A report on automation in the biopharma industr y has shown that the market is projected to grow at a compound annual growth rate (CAGR) of 5.7 Factors impacting the automation in the biopharma industry market The report found that 75 percent of pharmaceutical organisations want to use automated solutions more frequently.

article thumbnail

Red Sea Shipping Disruptions Don’t Have Pharma Companies Seeing Red Just Yet

MedCity News

Generic drugs are the pharmaceutical products mainly affected by the missile attacks disrupting shipping in the Red Sea. While the extra costs borne by drug companies aren’t causing an immediate spike in product prices, experts say they’ll eventually be factored into prices if the attacks become a long-term problem.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Your Ultimate Guide to Raw Materials Testing Support

PharmaTech

No bio/pharmaceutical product can be manufactured without first establishing the identity, purity and quality of its starting materials to ensure the product is suitable for its intended use. This guide covers all testing and considerations for raw materials supported at Eurofins BioPharma Product Testing.

article thumbnail

FDA Approves BioMarin Pharma’s Gene Therapy, the First for Hemophilia A

MedCity News

The regulatory decision makes the BioMarin Pharmaceutical product the first gene therapy for this inherited bleeding disorder. The FDA approved Roctavian for treating hemophilia A.

FDA 100
article thumbnail

Astellas Drug Acquired in $5.9B Deal Wins FDA Approval in Vision-Loss Disorder

MedCity News

The regulatory decision comes as safety concerns emerge around the first therapy for the disease, an Apellis Pharmaceuticals product. Izervay, a drug developed by Astellas Pharma subsidiary Iveric Bio, is now the second approved therapy for the degenerative vision-loss disorder geographic atrophy.

article thumbnail

Pfizer secures rights for RSV therapeutic candidate sisunatovir in China

Pharmaceutical Technology

In 2020, LianBio and Pfizer partnered to develop and commercialise transformative pharmaceutical products in Greater China. This deal excludes sisunatovir’s development and commercialisation rights in Mainland China, Singapore, Macau, and Hong Kong, which were previously licensed to LianBio in March last year.

article thumbnail

AbbVie’s blockbuster drug Skyrizi gets FDA nod for treating Crohn’s disease

MedCity News

In other drug decision news, the Rhythm Pharmaceuticals product Imcivree added the rare disease Bardet-Beidl syndrome as a new approved indication. AbbVie drug Skyrizi is now approved for Crohn’s disease, making it the first treatment for the disorder that addresses a particular protein associated with inflammation.